- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pinaverium May Provide Relief from Irritable Bowel Syndrome
A new study in Clinical Gastroenterology and Hepatology suggests that pinaverium may be a safe and effective treatment for Irritable Bowel Syndrome.
Pinaverium Bromide, an antispasmodic, is already in use in Europe, Canada and Mexico. But owing to the lack of original clinical studies, it is yet to be approved by the U.S. Food and Drug Administration (FDA).
Liang Zheng of the Nanjing University of Chinese Medicine who conducted this study says that his findings confirm the efficacy and effectiveness of pinaverium for IBS, which has no cure as of date. He concludes that pinaverium has the potential to become a viable first line drug for the treatment of IBS.
60 percent of the patients receiving pinaverium reported that their symptoms improved, as opposed to 34 percent in the control group. 29 percent of people receiving the drug reported no improvement while 11 percent felt that their symptoms had worsened.
There were no serious side effects recorded with pinaverium. 3.4% patients reported nausea, 3.2% from dizziness, 2.3% reported increase in blood pressure, while another 2.3% had abdominal discomfort.
IBS is a common chronic GI disorder that has high rates of recurrence.
Pinaverium Bromide, an antispasmodic, is already in use in Europe, Canada and Mexico. But owing to the lack of original clinical studies, it is yet to be approved by the U.S. Food and Drug Administration (FDA).
Liang Zheng of the Nanjing University of Chinese Medicine who conducted this study says that his findings confirm the efficacy and effectiveness of pinaverium for IBS, which has no cure as of date. He concludes that pinaverium has the potential to become a viable first line drug for the treatment of IBS.
60 percent of the patients receiving pinaverium reported that their symptoms improved, as opposed to 34 percent in the control group. 29 percent of people receiving the drug reported no improvement while 11 percent felt that their symptoms had worsened.
There were no serious side effects recorded with pinaverium. 3.4% patients reported nausea, 3.2% from dizziness, 2.3% reported increase in blood pressure, while another 2.3% had abdominal discomfort.
IBS is a common chronic GI disorder that has high rates of recurrence.
Next Story